Zealand Pharma A/S (OTCMKTS:ZLDPF) Now Covered by JPMorgan Chase & Co.

JPMorgan Chase & Co. started coverage on shares of Zealand Pharma A/S ( OTCMKTS:ZLDPF – Free Report ) in a research report report published on Friday, Marketbeat.com reports.

The brokerage issued an overweight rating on the stock. Zealand Pharma A/S Stock Up 3.5 % Shares of OTCMKTS:ZLDPF opened at $126.



00 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.

57 and a quick ratio of 35.57. The stock’s 50-day moving average price is $122.

70 and its two-hundred day moving average price is $116.15. Zealand Pharma A/S has a 12-month low of $41.

66 and a 12-month high of $141.74. Zealand Pharma A/S ( OTCMKTS:ZLDPF – Get Free Report ) last announced its quarterly earnings results on Thursday, August 15th.

The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.

06). The company had revenue of $4.93 million during the quarter, compared to analyst estimates of $0.

50 million. Zealand Pharma A/S had a negative net margin of 1,375.16% and a negative return on equity of 22.

95%. As a group, equities analysts expect that Zealand Pharma A/S will post -2.48 EPS for the current fiscal year.

About Zealand Pharma A/S Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

Further Reading Five stocks we like better than Zealand Pharma A/S Buy P&G Now, Before It Sets A New All-Time High 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion ESG Stocks, What Investors Should Know Monday.com’s Manic Price Pullback Is a Signal to Buy EV Stocks and How to Profit from Them 3 “Made in America” Stocks to Benefit From the Trump Presidency Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter .

.